Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2003

View Archived Issues

Aventis Behring submits BLA for i.v. alpha1-proteinase inhibitor

Alpha Therapeutic receives FDA approval for Aralast

Neurogen presents novel CRF1 modulators for anxiety, depression, IBS, etc.

Novel factor Xa inhibitors and their use covered by Millennium patent

NeuroSearch claims dual modulators of nicotinic receptors and monoamine transporters

New glycogen phosphorylase inhibitors discovered by Aventis researchers

AstraZeneca describes a nicotinic acetylcholine alpha7 agonist with cognition-enhancing properties

Novel series of adenosine A3 antagonists in early development at Sanofi-Synthelabo

Vertex scientists report inhibitors of GSK-3, Aurora-2 and Syk kinases

Captopril-allicin hybrids with antihypertensive and lipid- and insulin-lowering activity

Cyberonics reports one-year data from depression study

FDA committee discusses Replagal for Fabry's disease

Fabrazyme discussed by FDA advisory committee

Phase II trial of Advexin plus radiation shows tumor regression in NSCLC

Access licenses amlexanox to Zambon

Effect of AGI-1067 on atherosclerosis assessed in pivotal trial

Corixa and IDRI begin phase I trial of leishmaniasis vaccine

Phase II trial of MC-1 meets primary and secondary endpoints

Pain Therapeutics and Durect sign agreement to formulate long-acting opioid drugs

Preclinical antitumor profile of ST-1481, a new camptothecin derivative

Inhibition of COX-2 as a novel therapeutic option for acute pancreatitis

Strattera launched in the U.S.

Caelyx approved in E.U. for metastatic breast cancer

GSK launches Avodart for BPH in U.S.

FDA temporarily halts gene therapy trials using retroviral vectors in blood stem cells

Fujisawa and Sankyo form business arrangement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...